Table 1. Characteristics of the study population.
| Control n = 7 | NAFL1 n = 9 | NAFL2 n = 12 | NAFL3 n = 18 | NASH_Lds n = 15 | NASH_Vds n = 7 | |
|---|---|---|---|---|---|---|
| Gender F/M | 5/2 | 6/3 | 6/6 | 4/14 | 10/5 | 7/0# |
| Age (years) | 36.4 ± 5.2* | 49.7 ± 5.7 | 60.1 ± 3.5 | 61.1 ± 3.6 | 54.7 ± 2.5 | 54.6 ± 3.9 |
| BMI (kg/m2) | 21.0 ± 1.0 | 22.1 ± 1.1 | 26.1 ± 1.3* | 27.7 ± 0.8* | 31.5 ± 1.6* | 42.9 ± 1.8*† |
| Fasting glucose (mmol/L) | 6.1 ± 0.4 | 6.9 ± 1.3 | 5.1 ± 0.3 | 6.1 ± 0.4 | 7.2 ± 0.6 | 5.1 ± 0.2 |
| AST (normal range 0–65 IU/L) | 27.4 ± 2.5 | 18.5 ± 3.7 | 82.2 ± 52.1 | 29.2 ± 2.9 | 33.8 ± 3.1 | 35.4 ± 3.2 |
| ALT (normal range 0–65 IU/L) | 29.6 ± 4.2 | 19.0 ± 3.6 | 59.4 ± 24.2 | 34.7 ± 4.9 | 40.6 ± 5.1 | 49.9 ± 5.3 |
| γ-GT (IU/L) | 106.0 ± 41.3 | 50.4 ± 6.3 | 193.1 ± 93.6 | 83.5 ± 22.6 | 129.2 ± 29.8 | 36.7 ± 6.5*† |
| Alkaline phosphatase (IU/L) | 132.9 ± 42.8 | 87.8 ± 7.3 | 182.5 ± 68.0 | 91.0 ± 8.3 | 114.3 ± 25.7 | 69.9 ± 6.4 |
| Total bilirubin (mgL) | 14.3 ± 2.2 | 12.6 ± 2.4 | 11.6 ± 2.4 | 13.9 ± 1.8 | 10.4 ± 1.2 | 8.2 ± 1.7 |
| Albumin (g/L) | 37.4 ± 1.1 | 39.4 ± 0.9 | 38.5 ± 0.8 | 35.7 ± 0.8 | 37.8 ± 0.7 | 43.6 ± 1.4 |
| Platelets (giga/L) | 271.9 ± 40.5 | 252.6 ± 21.8 | 267.5 ± 32.6 | 224.2 ± 16.7 | 230.8 ± 26.3 | 279.0 ± 11.3 |
| Steatosis grade (%) | 0 | 15 ± 3 | 32 ± 8 | 53 ± 5 | 58 ± 6 | 81 ± 3 |
| NAFLD activity score (NAS) | 0.6 ± 0.2 | 1.3 ± 0.2 | 1.4 ± 0.2 | 2.5 ± 0.2 | 5.9 ± 0.2* | 5.0 ± 0* |
| Fibrosis stage, 0/1a/1b/1c/2/3 | ||||||
| n patients | 5/2/0/0/0/0 | 6/2/1/0/0/0 | 7/3/1/0/1/0 | 5/6/5/0/2/0 | 0/6/3/1/3/2 | 0/5/1/1/0/0 |
| (%), | (71/19/0/0/0/0) | (67/22/11/0/0/0) | (59/25/8/0/8/0) | (28/33/28/0/11/0) | (0/40/20/7/20/13) | (0/72/14/14/0/0) |
All patients are Caucasian. Data are expressed as mean ± SEM. The different groups were compared using ANOVA-test. *p < 0.05 versus Control (unpaired t-test); †p < 0.01 versus NASH_Lds (unpaired t-test). Genders repartition between the 5 groups of patients with p = 0.05317 and # between 6 groups of patients p = 0.008243 by Kruskal-Wallis rank sum test. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; F: female; γ-GT, gamma-glutamyl transferase; m: male; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis. Control, NAFL1, NAFL2, NAFL3 and NASH_Lds groups of patients selected at Paul Brousse Hospital (Villejuif, France). NASH_Vds are patients from L’Archet Hospital (Nice, France). NASH_Lds: learning dataset cohort; NASH_Vds: validation dataset cohort.